– SWITZERLAND, Lausanne / USA, MA – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov for her election to its Board of Directors at the AGM on June 26, 2023.
“Lila is a tremendous leader in the artificial intelligence (AI) and technology worlds, with robust experience in bringing companies to scale on a global level. As the founder of several technology companies throughout her career, her entrepreneurial spirit combined with her executive leadership skills and comprehensive experience in AI will complement and add depth to our board and help take SOPHiA GENETICS to the next level,” said CEO and Co-Founder, Jurgi Camblong.
About Lila Tretikov
An award-winning powerhouse in the global technology space, Lila Tretikov is currently Deputy CTO at Microsoft, where she previously served as Corporate VP in AI. Before joining Microsoft, Lila Tretikov was CEO and Vice-Chair of Terrawatt for two years and served as CEO of Wikipedia and Wikimedia.
“Throughout my career, I’ve focused on finding projects that create outsized socio-economic impact by leveraging cutting-edge technology. Artificial intelligence has the potential to create positive change for humanity, especially in medicine and biology,” said Lila Tretikov. “SOPHiA GENETICS is revolutionizing the healthcare industry and I am looking forward to working with them to help further their mission of democratizing data-driven medicine.”
Lila Tretikov currently serves as a board director for Onfido. She is also a member of the board of directors of Volvo Cars (Nasdaq: VOLCAR) and Xylem (NYSE: XYL).
She graduated from the University of California, Berkeley with a degree in Computer Science, Art, and Artificial Intelligence, and has completed executive graduate programs at Stanford University and the University of Oxford.
About SOPHiA GENETICS
SOPHiA GENETICS is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products, and services are currently used by a global network of hospital, laboratory, and biopharma institutions.
Source: SOPHiAGENETICS.COM
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
